Results presented at 72nd Annual Scientific Sessions of the ADA in Philadelphia
New data from a subgroup analysis of the A1chieve study show that intensifying treatment with NovoMix 30 (Biphasic insulin aspart) can significantly improve blood glucose control in people with type II diabetes with a reduced incidence of hypoglycemia. The results were presented at the 72nd Annual Scientific Sessions of the ADA in Philadelphia.
The results are from a subgroup analysis of 1,033 patients who were first treated with NovoMix 30 twice-daily then intensified to three-times daily over the 24-week study period. The results show that patients had significant improvements in their blood glucose control without compromising safety.
Before initiation with NovoMix 30, the average blood glucose control (HbA1c) among this subgroup of patients was (as high as) 9.8 per cent, despite the fact that 80.6 per cent were receiving oral glucose-lowering drugs. This figure is well above the American Diabetes Association (ADA) recommended target of seven per cent and such poor blood glucose control puts people at high risk of developing diabetes-related complications.
After 24 weeks of treatment with NovoMix 30 there was a significant reduction in HbA1c levels of 2.2 per cent, from 9.8 per cent to 7.6 per cent and in fasting plasma glucose by 76.3mg/dl from 204.5mg/dl to 128.20mg/dl. There were also significant reductions in post-breakfast plasma glucose level by 96.4mg/dl from 261.6mg/dl to 165.20mg/dl. The overall incidences of hypoglycaemia were reduced from 4.26 to 3.76 events/ person-year.
Commenting on the data, professor Philip Home said, “The study shows that premix insulin aspart when increased to three injections daily is an effective option for people with type II diabetes whether starting insulin or moving from other insulins. Improvements in blood glucose control of this magnitude would be of clinical importance to the people achieving it.”
EP News Bureau-Mumbai
